Summit Rock Advisors, LP - DAY ONE BIOPHARMACEUTICALS I ownership

DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 129 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is 2.14 and the average weighting 0.4%.

Quarter-by-quarter ownership
Summit Rock Advisors, LP ownership history of DAY ONE BIOPHARMACEUTICALS I
ValueSharesWeighting
Q3 2022$516,000
-13.0%
25,751
-22.3%
0.40%
-16.7%
Q2 2022$593,000
+80.2%
33,1250.0%0.48%
+140.8%
Q1 2022$329,000
-41.0%
33,1250.0%0.20%
-39.6%
Q4 2021$558,00033,1250.33%
Other shareholders
DAY ONE BIOPHARMACEUTICALS I shareholders Q3 2023
NameSharesValueWeighting ↓
Canaan Partners XI LLC 2,491,561$30,571,45326.81%
Atlas Venture Life Science Advisors, LLC 7,608,394$93,354,99414.46%
DAFNA Capital Management LLC 586,463$7,195,9012.24%
Nicholas Investment Partners, LP 2,188,654$26,854,7852.01%
RA Capital Management 7,809,852$95,826,8841.89%
BRAIDWELL LP 3,715,573$45,590,0811.44%
PFM Health Sciences, LP 2,224,598$27,295,8171.29%
SPHERA FUNDS MANAGEMENT LTD. 530,000$6,503,1001.18%
COMMODORE CAPITAL LP 739,661$9,075,6401.06%
Parkman Healthcare Partners LLC 466,408$5,722,8261.05%
View complete list of DAY ONE BIOPHARMACEUTICALS I shareholders